Lobe-specific responses of TRAMP mice dorsolateral prostate following celecoxib and nintedanib therapy

Autor(es)

Montico, Fabio ; Lamas, Celina de Almeida ; Rossetto, Isabela Maria Urra ; Baseggio, Andressa Mara ; Cagnon, Valeria Helena Alves

• Tipo de documento: Artigo Científico
• Fonte: Journal of Molecular Histology; v. 54, n. 4, p. 25-pg., 2023-06-19.

Resumo

Delayed cancer progression in the ventral prostate of the Transgenic Adenocarcinoma of the Mouse Prostate (TRAMP) model has been previously reported upon celecoxib and nintedanib co-administration. Herein, we sought to further investigate the effects of these drugs association in some of their direct molecular targets (COX-2, VEGF and VEGFR-2) and in reactive stroma markers (TGF-beta, alpha SMA, vimentin and pro-collagen 1) in the dorsolateral prostate, looking for lobe-specific responses. Male TRAMP mice were treated with celecoxib (10 mg/Kg, i.o.) and/or nintedanib (15 mg/Kg, i.o.) for 6 weeks and prostate was harvested for morphological and protein expression analyses. Results showed that combined therapy resulted in unique antitumor effects in dorsolateral prostate, especially due to the respective stromal or epithelial antiproliferative actions of these drugs, which altogether led to a complete inversion in high-grade (HGPIN) versus low-grade (LGPIN) premalignant lesion incidences in relation to controls. At the molecular level, this duality in drug action was paralleled by the differential down/upregulation of TGF-beta signaling by celecoxib/nintedanib, thus leading to associated changes in stroma composition towards regression or quiescence, respectively. Additionally, combined therapy was able to promote decreased expression of inflammatory (COX-2) and angiogenesis (VEGF/VEGFR-2) mediators. Overall, celecoxib and nintedanib association provided enhanced antitumor effects in TRAMP dorsolateral as compared to former registers in ventral prostate, thus demonstrating lobe-specific responses of this combined chemoprevention approach. Among these responses, we highlight the ability in promoting TGF-beta signaling and its associated stromal maturation/stabilization, thus yielding a more quiescent stromal milieu and resulting in greater epithelial proliferation impairment. (AU)

• Processo FAPESP: 18/16299-9 - Estudo in vivo e in vitro do papel da transição endotélio-mesenquimal na formação do estroma reativo associado ao adenocarcinoma de próstata no modelo TRAMP: influência de terapias antiangiogênica e anti-inflamatória
• Beneficiário: Fabio Montico
• Modalidade de apoio: Auxílio à Pesquisa - Regular